Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Randomized Controlled Study to Demonstrate Safety and Effectiveness of the BIOLOX Delta CoC THR System

NCT01921309 is registered in ClinicalTrials.gov with Corin as lead sponsor.

NCT NCT01921309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01921309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Randomized Controlled Study to Demonstrate Safety and Effectiveness of the BIOLOX Delta CoC THR System
Lead sponsor
Corin
Phase
Not applicable
Overall status
Unknown status
Start date
December 31, 2012
Completion date
December 31, 2021
Enrollment
342 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

avascular necrosis, cdh, osteoarthritis, rheumatoid arthritis